- The document discusses first trimester screening (FTS), which involves an NT scan and serum biochemistry between 11-13.6 weeks of pregnancy.
- FTS allows for early prediction, prevention, diagnosis and management of complications like aneuploidies, preeclampsia, fetal growth restriction, and preterm birth.
- The NT scan measures nuchal translucency thickness, which is increased in fetuses with chromosomal abnormalities. Combined with blood tests, FTS can assess risk for conditions like Trisomy 21, 18, 13, preeclampsia and more.
In this presentation we will discuss role of Doppler US in Infertility, fertilization and assisted fertilization.
we will discuss the favorable and unfavorable RI and PI.
We will discuss role of doppler us in various gynecological malignancies.
In this presentation we will discuss role of Doppler US in Infertility, fertilization and assisted fertilization.
we will discuss the favorable and unfavorable RI and PI.
We will discuss role of doppler us in various gynecological malignancies.
Nuchal translucency
It is a sonographic pre natal screening scan to detect cardiovascular abnormality in a fetus.
NT can also detect altered extra cellular matrix composition and limited lymphatic drainage
When a lady visits her Obstetrician, she may be advised Ultrasonography Scan at some stage in pregnancy. It is a frequently asked question as to how many scans should she undergo during pregnancy? When? Why? (for what purpose?). I have explained this in simplified manner. Ultrasonography is an ideal and safe screening tool in pregnancy.
Nuchal translucency
It is a sonographic pre natal screening scan to detect cardiovascular abnormality in a fetus.
NT can also detect altered extra cellular matrix composition and limited lymphatic drainage
When a lady visits her Obstetrician, she may be advised Ultrasonography Scan at some stage in pregnancy. It is a frequently asked question as to how many scans should she undergo during pregnancy? When? Why? (for what purpose?). I have explained this in simplified manner. Ultrasonography is an ideal and safe screening tool in pregnancy.
this is what we presented at AICOG 2012 varanasi .............USG A WATCH DOG FOR PREGNANCY...................please let me know what more any one wants to see, i can keep uploading my presentations.....
What do you mean by Anomaly? What are its types? Is Anomaly Scan a ‘MUST’?
In our family there has been no case of Anomaly.
I have already undergone FTS, So will it give any additional information?
Can it guarantee that my fetus is 100% normal? If an abnormality is found, can it be cured?
What options are available if an Anomaly is detected?
Can it Surely (100%) rule out Down’s Syndrome?
Can Anomaly be 100% prevented?
If such questions arise in your mind, please watch my eight small videos on this subject.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
Explore our infographic on 'Essential Metrics for Palliative Care Management' which highlights key performance indicators crucial for enhancing the quality and efficiency of palliative care services.
This visual guide breaks down important metrics across four categories: Patient-Centered Metrics, Care Efficiency Metrics, Quality of Life Metrics, and Staff Metrics. Each section is designed to help healthcare professionals monitor and improve care delivery for patients facing serious illnesses. Understand how to implement these metrics in your palliative care practices for better outcomes and higher satisfaction levels.
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
Defecation
Normal defecation begins with movement in the left colon, moving stool toward the anus. When stool reaches the rectum, the distention causes relaxation of the internal sphincter and an awareness of the need to defecate. At the time of defecation, the external sphincter relaxes, and abdominal muscles contract, increasing intrarectal pressure and forcing the stool out
The Valsalva maneuver exerts pressure to expel faeces through a voluntary contraction of the abdominal muscles while maintaining forced expiration against a closed airway. Patients with cardiovascular disease, glaucoma, increased intracranial pressure, or a new surgical wound are at greater risk for cardiac dysrhythmias and elevated blood pressure with the Valsalva maneuver and need to avoid straining to pass the stool.
Normal defecation is painless, resulting in passage of soft, formed stool
CONSTIPATION
Constipation is a symptom, not a disease. Improper diet, reduced fluid intake, lack of exercise, and certain medications can cause constipation. For example, patients receiving opiates for pain after surgery often require a stool softener or laxative to prevent constipation. The signs of constipation include infrequent bowel movements (less than every 3 days), difficulty passing stools, excessive straining, inability to defecate at will, and hard feaces
IMPACTION
Fecal impaction results from unrelieved constipation. It is a collection of hardened feces wedged in the rectum that a person cannot expel. In cases of severe impaction the mass extends up into the sigmoid colon.
DIARRHEA
Diarrhea is an increase in the number of stools and the passage of liquid, unformed feces. It is associated with disorders affecting digestion, absorption, and secretion in the GI tract. Intestinal contents pass through the small and large intestine too quickly to allow for the usual absorption of fluid and nutrients. Irritation within the colon results in increased mucus secretion. As a result, feces become watery, and the patient is unable to control the urge to defecate. Normally an anal bag is safe and effective in long-term treatment of patients with fecal incontinence at home, in hospice, or in the hospital. Fecal incontinence is expensive and a potentially dangerous condition in terms of contamination and risk of skin ulceration
HEMORRHOIDS
Hemorrhoids are dilated, engorged veins in the lining of the rectum. They are either external or internal.
FLATULENCE
As gas accumulates in the lumen of the intestines, the bowel wall stretches and distends (flatulence). It is a common cause of abdominal fullness, pain, and cramping. Normally intestinal gas escapes through the mouth (belching) or the anus (passing of flatus)
FECAL INCONTINENCE
Fecal incontinence is the inability to control passage of feces and gas from the anus. Incontinence harms a patient’s body image
PREPARATION AND GIVING OF LAXATIVESACCORDING TO POTTER AND PERRY,
An enema is the instillation of a solution into the rectum and sig
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
1. 11-13.6 WEEKS SCREENING :
NT SCAN & S. BIOCHEMISTRY
FTS : FIRST TRIMESTER SCREENING
PAST, PRESENT AND FUTURE
FAQs
Dr. Nisheeth M. Oza
2. Dr. Nisheeth M. Oza
M.D., D.G.O., F.C.P.S., D.N.B., (M.N.A.M.S.) (OBGYN)
D.A., M.B.B.S., Dip. YAN
Obstetrician, Gynaecologist, Infertility Consultant,
FMF Certified Ultrasonographer (FMF ID 145907)
Licensed for Aneuploidy Screening NT, NB, DV, Cervix & PIH Screening.
Diploma in Yoga, Ayurveda & Naturopathy
Dr. Oza’s Hospital 87/7, Panvel 410206, Maharashtra India.
Email : drnmozas@gmail.com
Website : drozashospital.com
YouTube : DrOzaConnects
3. In last 30 years, there have been a lot of developments in FTS,
which have inverted the pyramid of Antenatal Care.
Previously one would only come to know about complications in 3rd
Trimester when pregnant women developed Pre-eclampsia or FGR or
had Preterm Birth or after delivery would know that the Newborn had
Down Syndrome or a major structural abnormality.
4. Now, instead of waiting helplessly till third trimester, the focus has shifted to
11-13.6 weeks Screening, with the opportunity for prediction, prevention,
early diagnosis & proactive management of such complications of pregnancy.
5. WHAT TO SCREEN FOR? WHY SCREEN?
1] FOR ANEUPLOIDY e.g. Trisomy 21, 18, 13 :
• Many abort , few have IUFD (Stillbirth).
• Trisomy 18, 13 : Survive only for few hours or days after birth.
• Trisomy 21 : may live upto 49 years, but MR, health problems, financial burden.
2] FOR PRE-ECLAMPSIA & FGR :
• PE – Increased Maternal Mortality, Morbidity.
• FGR- Increases IUFD (Stillbirth), MAS, Neonatal Morbidity.
3] FOR PRETERM BIRTH : Increased Neonatal Mortality, Morbidity.
4] SELECTED CONGENITAL ANOMALIES DETECTABLE AT 11-14 WEEKS :
• Only 10 out of 100.
• Counsel : Compatible with life? Surgery required? Prognosis. Decision making.
6. DEFINITION OF NT & ITS IMPORTANCE
• Definition : NT is the sonographic appearance of collection of fluid
under the skin behind the neck of the fetus in the First Trimester of
pregnancy.
ITS IMPORTANCE IN SUSPECTING ANEUPLOIDY
Median NT
Normal (Euploid) group 2.0 mm
Trisomy 21 3.4 mm
Trisomy 13 4.0 mm
Trisomy 18 5.5 mm
Turner’s Syndrome 9.2 mm
7. EVOLUTION OF FTS
• Trisomy 21 Downs Syndrome was first described in 1866 (156 years ago).
• Trisomy 18 (Edward S.) & Trisomy 13(Patau S.) first described in 1960 (62
years ago).
• Association of advanced Maternal Age & Tri 21 first described in 1909.
First the Invasive Tests were introduced for maternal age > 35 yrs.
1970s Amniocentesis (42 Years ago)
1980 CVS
However, 80% of DS were born to mothers < 35 years and it was not possible
to justify so many invasive tests for age more than 35 years.
Therefore, need for Screening tests was felt, so that these can be offered to
all pregnant women in the First Trimester.
Necessity is the mother of invention.
8. Amongst the SCREENING TESTS available clinically
• 1988 : Triple Marker Test
• 1994 : Double Marker Test
• 2003 : NT Scan Kypros Nicolaides & FMF (work 1992-2002)
• 2005 : Combined Test – NT + Double Marker Test
• 2008 : Quadruple Marker Test
• 2008 : NIPS
9. EVOLUTION OF NT SCAN, FMF, Courses,
Certification, License
• 1866 – John Langdon Down – Tri 21 – Skin appears to be too large (thick) for their
body.
• 1992 – BMJ – Kypros Nicolaides – excessive accumulation of subcutaneous fluid
behind fetal neck, which could be visualized by ultrasonography as raised NT in
3rd month of pregnancy.
• This was the game changer.
• He founded Fetal Medicine Foundation in UK in 1995. Extensive research by him,
by FMF & multicenter trials between 1992 & 2002 approved his findings & 11 to
13.6 weeks scan became widely used in 2003.
• FMF did standardization of 11-13.6 weeks’ scan.
• FMF runs Online Courses for each of parameter of FTS, conducts exams, does
Certification for each parameter, & has provision of software, licensing & annual
audit & annual renewal of this license under its strict control.
10. PURPOSE OF THIS SCREENING : AIM & OBJECTIVES
• To screen for Aneuploidy : Trisomy 21, 18, 13.
• To screen for likelihood of developing Pre-eclampsia.
• To screen for likelihood of developing FGR.
• First assessment of the length of Cervix.
• Early detection of certain Structural Anomalies in fetus (10 out of
100).
11. PRETEST COUNSELING :
• Aneuploidy : Deviation from normal Chromosomal make up, be it in
number or structure.
• Trisomy : Presence of an extra Chromosome at a particular pair of
Chromosomes eg. Trisomy 21, 18, 13.
• What if your fetus has increased NT &/or NB is not visualized?
It means greater risk of Trisomy, structural defect, cardiac defect.
Definitive Diagnostic Invasive Test (CVS) is indicated if NT > 3.0 mm.
12. • What if your fetus has normal NT value?
Detection Rate of NT Scan for Trisomy 21(DS) is 80%, so you can add Serum
Biochemistry (Double Marker Test) to increase DR of Tri 21 to 90%.
Addition of other Sonographic markers like absent/hypoplastic NB, reversal
of a wave in DV, TR, may further increase DR of Tri 21 to 95%.
• What if Screening (Ute. Art. PI) shows increased risk for developing PE or
FGR?
You may be offered Tab. Aspirin 150 mg/day as Prophylaxis, from day of
screening till 34 or 36 weeks of pregnancy.
• How is the first assessment of length of Cervix on TVS useful?
It serves as baseline for comparing at time of further assessment of length of
Cervix, may be at time of Anomaly Scan (18-22 weeks)or earlier if indicated
by History.
13. Progressive shortening of length of Cervix or funneling of Cervix or
length < 25 mm on TVS, indicates high risk of Preterm birth/Second
Trimester loss.
So what can be done for that?
1] Cervical Cerclage (Tightening of Os) Operation.
OR
2] Progesterone ( 400 mg vaginally daily at bedtime) till 34 or 36 weeks
of pregnancy.
14. ASSIGNING PRETEST RISK
Before doing the scan, Data is fed from History, like :
• Mother’s age at the time of delivery.
• Race.
• Number of previous children (Parity).
• Previous Miscarriages.
• Aneuploidy in prior pregnancy & which one?
• History of smoking.
• Maternal Diabetes Mellitus.
• Natural or IVF Conception?
• Chronic HT, SLE, APLA Syndrome.
• Did patient’s mother have Pre-eclampsia?
15. FROM EXAMINATION :
• Height in cm.
• Current Maternal Weight in Kg.
From this, Pretest Aneuploidy Risk is assigned by the software ie. FMF
Software.
16. 11-13.6 WEEKS SCAN : PARAMETERS INCLUDED
Scan by trained FMF licensed sonographer or by sonographer following
Criteria laid down by FMF :
• CRL : Accurate GA, Dating.
• NT, NB : For Aneuploidy.
• DV (reversed a wave) : Increased chances of Aneuploidy, Cardiac Defects,
fetal Deaths.
• TR : Increased chances of Aneuploidy, Cardiac Defects.
• Ute. Art. PI : Screening for Pre-eclampsia, FGR.
• Cervix Length (TVS) : Subsequent Scan-Shortening- predict PT Del.
• Detectable Anomaly : 10 out of 100.
• DOUBLE MARKER : PAPP-A, Free Beta-hCG.
• DOUBLE MARKER + PlGF : PAPP-A, Free Beta-hCG, PIGF.
17. DETECTION RATE OF ANEUPLOIDY AND PE
Trisomy 21 DR FPR
Age alone Low
Double Marker Test alone 65% 5%
NT Scan alone (Properly Performed by FMF norms) 80% 5%
NT + Double Marker (Standardized Lab) 90% 5%
NT + Double Marker + NB 93% 5%
NT + Double Marker + NB + DV + TR 95% 3%
Trisomy 18 & 13
NT + Double Marker + NB + DV + TR 75% 5%
PE
Ute. Art. PI (NT Scan) + Double Marker 84% 5%
Ute. Art. PI (NT Scan) + Double Marker + PIGF 93%
18. POST TEST COUNSELING FOR ANEUPLOIDY
• NT > 3mm or Cystic Hygroma : Increased Chromosomal &/or
Structural abnormality. Therefore, Offer Diagnostic Test : CVS < 14
weeks (or Amniocentesis > 16 weeks).
• NT < 3mm : Add Double Marker Test (Combined Test).
• If Low risk (1 n 1000) – Aneuploidy Unlikely – Reassure.
• If High risk (> 1 in 250) – Means statistical likelihood of Chromosomal
abnormality. Offer Diagnostic Test – CVS/Amniocentesis.
• If Intermediate risk (1 in 250 to 1 in 1000) Counsel – consider NIPS.
NIPS report : Low risk – Reassuring.
High risk – Offer Diagnostic Test – CVS/Amniocentesis.
19. • NIPS Screening Test, avoids Invasive Test,
Low risk – reassuring ;
High risk – Offer Diagnostic Invasive Test : CVS, rarely false positive.
After Invasive Test, patient may have some bleeding pv, Miscarriage
rate 1 in 300.
NIPS (cf DNA) DR(Sensitivity) (FPR : 0.04%)
Trisomy 21 99%
Trisomy 18 93%
Trisomy 13 99%
20. POST TEST COUNSELING FOR PRE-ECLAMPSIA & FGR
Low risk – reassure – Routine Antenatal Care.
High risk – Offer Tab. Aspirin 150 mg/day till 34-36 weeks.
POST TEST COUNSELING FOR PRETERM BIRTH
If previous history of Preterm Birth or HSO Insufficient Cervix or Cervix
Length < 25 mm on TVS or Shortening noticed in subsequent scans :
OFFER
1] Cervical Cerclage : Tightening of OS operation. Or
2] Progesterone 400 mg/day vaginally till 36 weeks.
21. POST TEST COUNSELING FOR STRUCTURAL ANOMALIES
IF ANY DETECTED
• 10 out of 100 are detectable.
Eg. - Anencephaly (Absence of Forebrain)
- Acrania (Absence of Skull)
COUNSELING :
• These two are uniformly lethal, cannot survive after birth.
22. For other Anomalies :
• Associated Chromosomal abnormalities–confirm by Invasive Test-CVS.
• Brief explanation about the anomaly.
• Its natural course, during pregnancy & after birth.
• Need for surgery after birth.
• Prognosis : Quality of life, Level of disability. Long term Outcome.
• Help in nondirective manner. Help in decision making.
• Management respecting couple’s informed choices.
23. COST OF VARIOUS SCREENING TESTS IN NAVI MUMBAI TODAY
TEST COST IN INR
NT Scan 2,500/-
Double Marker Test 2,500/-
Double Marker Test + PIGF 3,500/-
NIPS (BASIC) 13,000/-
LABORATORY COST OF DIAGNOSTIC TESTS
CVS 15,000/-
Amniocentesis 15,000/-
24. FOLLOW UP AFTER DIAGNOSTIC TEST CONFIRMS ANEUPLOIDY
• Non-directive Counseling – Natural history during pregnancy, after
birth.
• Survival after birth.
• Prognosis.
• Informed Decision Making.
25. FOLLOW UP AFTER INCREASED NT, but NORMAL
KARYOTYPE (CVS)
• Incidence of structural defect in this group is higher.
• Repeat Ultrasound at 15 weeks & Anomaly Scan at 18-22 weeks.
• Fetal 2-D Echo at 22-24 weeks.
FOLLOW UP OF MAJOR STRCTURAL ANOMALY &
CONTINUING PREGNANCY
• Multidisciplinary Team Approach.
• Delivery in Tertiary Care Centre with high quality Neonatal Care
available.
26. FAQs AFTER FTS : 11-13.6 WEEKS SCREENING
1] NT > 3 mm – Increased chromosomal & structural abnormality – why
not do MTP directly?
• In certain % of cases, NT may resolve after 14 weeks – Normal
Outcome. NT scan is a screening test.
• Diagnostic Test (CVS or Amniocentesis) is important for KT, important
to help parents in decision making & also define recurrence risk.
2] NT > 3 mm & major structural anomaly, why not do MTP directly?
• Diagnostic Test – find out Etiology of Increased NT & calculate
recurrence risk of that condition.
27. 3] FTS is low risk, so is everything fine?
• Congratulations. FTS has shown low risk, which is quite reassuring.
Very very small % of false negative may be there.
Friends, as far as structural anomalies are concerned at this stage, CRL
is only 6 cm & only 10 out of 100 anomalies can be detected at this
stage, so Anomaly Scan at 18-22 weeks is the next step. Some evolving
anomalies can be detected in 3rd trimester/after birth.
4] What will be the Recurrence Risk of Aneuploidy/Structural Anomaly?
• Depends on the Aneuploidy or Structural Anomaly Diagnosed.
5] What is the role of Quadruple Marker Test in Screening?
• It might have some role in those who missed FTS for some reason.
28. FUTURE OF FTS
1] Will NIPS replace NT Scan (11-13.6 weeks scan)?
• No, NIPS can only predict Aneuploidy risk, NT Scan can do 4 more
things.
2] Will NIPS replace Dual Marker Test?
• Yes it will, as it has higher DR (Sensitivity), When? As soon as the cost
comes down.
3] FUTURE WILL BE ‘SUPPEMENTARY FTS or TESTING’ ie. NT Scan +
NIPS.
29. Remember 3 things :
1] For FTS, proper Pre Test & Post Test Counseling & following a
protocol are very important.
2] FTS today is NT + Double Marker Test.
3] FTS tomorrow will be NT + NIPS.